Outcome of Board Meeting

October 01, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Ltd. BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Dear Sir/Madam, Subject: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") Ref: Disclosure under Regulations 30 of the SEBI Listing Obligations. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals, as may be applicable, has, inter alia, considered and approved the following matters: 1. Adoption of Bliss GVS Pharma Limited - Senior Executive Employee Stock Option Policy 2026 (“Senior Executive ESOP 2026” / “SE ESOP 2026”); 2. Adoption of Bliss GVS Pharma Limited - Employee Stock Option Policy 2026 (“Employee ESOP 2026”); and 3. Grant of stock options equal to or exceeding 1% of issued capital to identified employees during any one year. in accordance with the provisions of Companies Act, 2013 (and the rules made thereunder) and Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (“SEBI SBEB SE Regulations, 2021”), subject to the approval of members of the Company. In this regard, brief details in accordance with the SEBI Listing Regulations read with read with Master Circular Ho/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, attached as Annexure- A and Annexure B respectively. The meeting of the Board of Directors commenced at 15:37 p.m. and concluded at 16:55 p.m. The above is being made available on the Company’s website, i.e. https://www.blissgvs.com/. Kindly take the above information on your record and acknowledge. Thanking you, Yours Faithfully, For Bliss GVS Pharma Limited Aditi Bhatt Company Secretary & Compliance Officer Encl.: As above Annexure A Particulars Bliss GVS Pharma Limited - Senior Executive Employee Stock Option Plan 2026 (“Senior Executive ESOP 2026” / “SE ESOP 2026”) Brief details of options granted The aggregate number of Stock Options proposed to be granted under the Senior Executive ESOP 2026 shall not be exercisable into more than 26,50,000 equity shares corresponding to ~2.49% of the paid-up equity share capital of the Company, on fully diluted basis, in one or more tranches. whether the scheme is in terms of SEBI Yes, the Senior Executive ESOP 2026 is in terms (SBEB) Regulations, 2021 (if applicable); of SEBI SBEB SE Regulations, 2021. Total number of shares covered by these 26,50,000 Equity Shares options Pricing Formula The exercise price for each option shall be at a discounted fixed price of INR 10/-. Options Vested Not Applicable, as this outcome is pertaining to approval of the Scheme by the Board of Directors. Time within which option may be exercised The vested Options shall be exercisable according to the terms and conditions as determined and set forth under the Senior Executive ESOP 2026. Brief details of significant terms The Senior Executive ESOP 2026 shall be administered by the Nomination and Remuneration Committee, which will function as the Compensation Committee for the purposes of the Scheme. The Senior Executive ESOP 2026 shall be implemented through the issuance of new equity shares by the Company. The grant of stock options under the Senior Executive ESOP 2026 shall be made to eligible employee in accordance with the Scheme. There shall be a minimum period of one (1) year between grant of options and vesting of options. The granted Options once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Senior Executive ESOP 2026. Options Exercised Money Realised by exercise of options The total number of shares arising as a result of exercise of options Options Lapsed Not Applicable, as this outcome is pertaining Variation of terms of options to approval of the Scheme by the Board of Directors. Subsequent changes or cancellation or exercise of such options Diluted earnings per share pursuant to issue of equity shares on exercise of options Annexure B Particulars Bliss GVS Pharma Limited - Employee Stock Option Policy 2026 (“Employee ESOP 2026”) Brief details of options granted The aggregate number of Stock Options proposed to be granted under the Employee ESOP 2026 shall not be exercisable into more than 47,00,000 equity shares corresponding to ~4.42% of the paid-up equity share capital of the Company, on fully diluted basis, in one or more tranches. whether the scheme is in terms of SEBI Yes, the Employee ESOP 2026 is in terms of (SBEB) Regulations, 2021 (if applicable); SEBI SBEB SE Regulations, 2021 Total number of shares covered by these 47,00,000 Equity Shares options Pricing Formula The exercise price for each option shall be a discounted fixed price of INR 10/- Options Vested Not Applicable, as this outcome is pertaining to approval of the Scheme by the Board of Directors. Time within which option may be exercised The vested Options shall be exercisable according to the terms and conditions as determined and set forth under the Employee ESOP 2026. Brief details of significant terms The Employee ESOP 2026 shall be administered by the Nomination and Remuneration Committee, which will function as the Compensation Committee for the purposes of the Scheme. The Employee ESOP 2026 shall be implemented through the issuance of new equity shares by the Company. The grant of stock options under the Employee ESOP 2026 shall be made to eligible employees in accordance with the eligibility criteria prescribed under the Scheme. There shall be a minimum period of one (1) year between grant of options and vesting of options. The granted Options once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Employee ESOP 2026. Options Exercised Money Realised by exercise of options The total number of shares arising as a result of exercise of options Options Lapsed Not Applicable, as this outcome is pertaining Variation of terms of options to approval of the Scheme by the Board of Directors. Subsequent changes or cancellation or exercise of such options Diluted earnings per share pursuant to issue of equity shares on exercise of options